The development of platelet glycoprotein IIb/IIIa antagonists for ischemic cardiovascular disease required well-controlled, large clinical trials to establish efficacy and safety and overcome skepticism.
The development of GP IIb/IIIa antagonists required integrating diverse data and conducting large clinical trials to overcome skepticism and establish safety and efficacy.
The rationale for developing platelet glycoprotein (GP) IIb/IIIa antagonists as antithrombotic agents for use in ischemic cardiovascular disease emerged from integrating data obtained in the early 1980s by many different investigators working in diverse fields. The data were, however, often controversial or fragmentary, or required extrapolation to human disease from in vitro systems or animals models. Thus, for those who are considering embarking on a similar adventure in drug development, it is important to emphasize that until efficacy and safety was established for these agents in well-controlled, large clinical trials, many individuals remained skeptical about the potential benefits and safety of this approach.
Barry S. Coller (Wed,) conducted a review in Ischemic cardiovascular disease. Platelet glycoprotein (GP) IIb/IIIa antagonists was evaluated. The development of platelet glycoprotein IIb/IIIa antagonists for ischemic cardiovascular disease required well-controlled, large clinical trials to establish efficacy and safety and overcome skepticism.